# Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting
Canonical URL: https://biopharmsignal.com/news/CNTX/context-therapeutics-highlights-ct-95-and-ct-202-programs-at-2025-sitc-annual-meeting
Ticker: CNTX
Company: Context Therapeutics
Source: Context Therapeutics
Published: 2025-11-07 12:30 EST
Original Source URL: https://ir.contexttherapeutics.com
## Summary

PHILADELPHIA, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today shared two posters discussing the Company’s CT-95 and

## Article Body
PHILADELPHIA, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today shared two posters discussing the Company’s CT-95 and
## Recent Company News
- 2026-05-27 11:30 EST — [Context Therapeutics to Present at the Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/CNTX/context-therapeutics-to-present-at-the-jefferies-global-healthcare-conference) — Source: Context Therapeutics
- 2026-05-18 10:45 EST — [Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202](https://biopharmsignal.com/news/CNTX/context-therapeutics-enters-into-license-agreement-amendment-with-bioatla-for-ct-202) — Source: Context Therapeutics
- 2026-05-06 20:18 EST — [Context Therapeutics Reports First Quarter 2026 Operating and Financial Results](https://biopharmsignal.com/news/CNTX/context-therapeutics-reports-first-quarter-2026-operating-and-financial-results) — Source: Context Therapeutics
- 2026-04-02 11:30 EST — [Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer](https://biopharmsignal.com/news/CNTX/context-therapeutics-announces-ctim-76-receives-fda-fast-track-designation-for-the-treatment-of-platinum-resistant-ovarian-cancer) — Source: Context Therapeutics
- 2026-03-23 20:16 EST — [Context Therapeutics Reports Full Year 2025 Operating and Financial Results](https://biopharmsignal.com/news/CNTX/context-therapeutics-reports-full-year-2025-operating-and-financial-results) — Source: Context Therapeutics
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)